Stanford University

Anesthesia-Masked Psilocybin Therapy for Major Depression

Start Date

July 1, 2026

Compounds

Psilocybin, Placebo

Propofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression (PEAK)

Start Date

January 28, 2025

Compounds

Ketamine, Placebo

Examining Mu Opioid Mechanisms of Ketamine’s Rapid Effects in OCD (MKET2) (MKET2)

Start Date

February 24, 2024

Compounds

Ketamine, Placebo

Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure

Start Date

November 15, 2021

Stanford Reward Circuits of the Brain Study – MDMA

Start Date

May 1, 2021

Compounds

MDMA, Placebo

Opiate Suicide Study in Patients With Major Depression

Start Date

August 1, 2020

Compounds

Ketamine, Placebo

Intraoperative Ketamine Versus Saline in Depressed Patients Undergoing Anesthesia for Non-cardiac Surgery

Start Date

August 22, 2019

Compounds

Ketamine, Placebo

Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)

Start Date

September 1, 2016

Compounds

Ketamine, Placebo

Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

Start Date

December 1, 2014

Compounds

Ketamine, Placebo

General Anesthesia and Discrete Components of Ketamine Neurophysiology

This cohort study (n=52) examined how general anaesthesia changes ketamine’s brain activity patterns in healthy volunteers, surgical patients and people with depression. Ketamine given during general anaesthesia kept its beta-gamma effects but lost the usual theta increase, suggesting these neurophysiological components can be separated.

Published

April 8, 2026

Journal

JAMA Psychiatry

Authors

Deverett, B., Li, D., Lii, T. R., Vlisides, P. E., Tarnal, V., Forsyth, A., Sumner, R., Sikka, P., Schatzberg, A. F., Muthukumaraswamy, S., Mashour, G. A., Heifets, B. D.

Increased cortical thickness and decreased brain age among special operations veterans with blast TBI after a magnesium-ibogaine protocol

This secondary analysis of an observational study (n=30) - named MISTIC - of Special Operations Forces veterans with blast-related traumatic brain injury, examined ibogaine given with magnesium and found increased cortical thickness, larger subcortical volumes and a lower estimated brain age one month later. The authors note that the MRI changes could reflect neuroplastic effects, although the scans may also be influenced by non-structural factors.

Published

February 21, 2026

Journal

iScience

Authors

Geoly, A. D., Coetzee, J. P., Buchanan, D. M., Struckmann, W., Kim, B., Sridhar, M., Azeez, A., Lissemore, J. I., Cherian, K., Faerman, A., Keynan, J. N., Singal, P., Shanbour, A., Bandeira, I. D., Kratter, I. H., Adamson, M. M., Saggar, M., Rolle, C., Williams, N. R.

Magnesium-ibogaine therapy in veterans with traumatic brain injuries

This observational study (n=30) evaluates ibogaine (up to 980mg/70kg) in combination with magnesium (1-2 hours before and 12 hours later) in male Special Operations Forces veterans with predominantly mild traumatic brain injury (mTBI). The study assessed changes in disability, PTSD, depression, and anxiety immediately and one month after treatment using various scales. Results show significant improvements in functioning and psychological symptoms with no serious adverse events.

Published

January 5, 2024

Journal

Nature Medicine

Authors

Cherian, K. N., Keynan, J. N., Anker, L., Faerman, A., Brown, R. E., Shamma, A., Keynan, O., Coetzee, J. P., Batail, J. M., Phillips, A., Bassa, N. J., Sahlem, G. L., Inzunza, J., Millar, T., Dickinson, J., Rol, C. E., Keller, J., Adamson, M., Kratter, I. H., Williams, N. R.